Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
A phase 2 trial of single dose of CNCT19 in acute lymphoblastic leukaemia, run by Juventas Cell Therapy Ltd., now recruiting.
Overview
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia is a phase 2 interventional study registered as NCT04684147 by Juventas Cell Therapy Ltd., with 100 participants planned, started 2020-12-24 and due to reach its primary completion in 2022-09-22. Interventions recorded: single dose of CNCT19.
Similar pages
not linked directly; found by shared links- TrialA Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialCAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialStudy of YK012 in B-cell Acute Lymphoblastic Leukemia
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialAZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA Study of CTD402 in T-ALL/LBL Patients
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialA Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialStudy of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Shares Acute lymphoblastic leukaemia and the tag pipeline.
- TrialStudy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Shares Acute lymphoblastic leukaemia and the tag pipeline.